After spending 30+ years in ICU's as a practicing surgeon, to me the info on Zovant is good. To save only 20% of those terminal/preterminal patients on respirators and multiple invasive central lines is superb ( unless you happen to be a Fed bean counter looking to save a few bucks) Its all in your philosophy...and perhaps the monies would be better spent on the young and productive. I am ambivalent at this point. (though I am on the Medicare dole as we speak)
There's a Salomon report recently regarding Zovant and the outlook of LLY in 2001-2002.
Since result of Zovant trial gives only a mediocre 19.4% lower risk of death than those taking placebos, the drug will contribute little to 2001 earnings. With declining sales of Prozac, LLY is expecting single-digit % growth in 2001-2002, as compared with Pfizer and Pharmacia's predicting growth of 20% to 25% range. In this scenario, LLY will have to live through a difficult period between now and then.
This is bad, but this is what they have reported. Any comment, anybody?
as a doc, perhaps you can shed some light here--if Zovant is pretty much the only choice out there and even if it saves "only" 20% of these pts, wouldn't docs be obligated to try it? will they be able to determine if they should or should not use it prior to administration? (like the data we know have on the clot-buster drugs) Seems like the lawyers, who unfortunately dictate 'the standard of care' would have a field day with plans and hospitals that deny a pt this drug.
8iron, Sorry for the delay. Yes, I do think that the docs would be obligated to consider the drug despite the cost; however, it would be an individual decision based on many factors, such as the primary dx, mental facilities, quality of life (whatever that is), families wishes, and paramount, the wishes of the patient, if he or she is capable of rendering a rational decision. Probably not much of an answer. I spent 5-6 years working on hospital Ethics committees wrestling with such dilemmas...probably that contributed to my slightly early retirement. Yet I feel Zovant could be a significant advance, when used properly. (its use will probably be monitored by some hospital committee).